查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1767761

结核病诊断市场：产业分析、规模、份额、成长、趋势和预测（2025-2032）

Tuberculosis Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 177 Pages | 商品交期: 2-5个工作天内

价格
简介目录

主要发现

  • 结核病诊断市场规模：24亿美元（2025年）
  • 预计市场价值：35亿美元（2032年）
  • 全球市场成长率：5.5%（2025年至2032年的复合年增长率）

结核病诊断市场 - 报告范围

结核病是一种严重影响全球健康问题的重大感染疾病，结核病诊断在结核病的检测和管理中发挥着至关重要的作用。这些诊断工具涵盖从传统的涂片显微镜检查到能够快速且准确地检测结核桿菌和抗药性模式的先进分子检测。结核病诊断市场服务于医院、诊断实验室、诊所和照护现场机构等各种医疗机构，并提供多样化的检测组合，例如基于培养的方法、核酸增幅检查(NAAT)、结核菌素皮肤试验、干扰素γ释放试验 (IGRA) 和X射线检测。推动市场成长的因素包括全球持续的结核病负担、对早期发现和疾病控制的持续投入，以及提高检测准确性和周转时间的技术进步。

市场成长动力

全球结核病诊断市场受多种因素驱动，例如持续的高结核病发病率，尤其是在医疗基础设施欠发达的发展中地区。世界卫生组织的「终结结核病策略」等日益兴起的全球倡议强调早期诊断和有效治疗，这推动了对创新诊断解决方案的需求。快速分子诊断和自动化平台开发等技术进步正在提高结核病的检出率，并促进抗药性分析，从而实现更好的病例管理和疫情控制。此外，就地检验的日益普及，扩大了及时获得结核病诊断的机会，尤其是在资源匮乏的地区，这进一步推动了市场扩张。

市场限制

儘管成长前景光明，结核病诊断市场仍面临诸多挑战，例如先进诊断检测的高昂成本、低收入地区检测基础设施的匮乏，以及与结核病相关的社会污名化阻碍了及时检测和诊断。复杂的监管要求和冗长的新产品核准流程也构成了市场准入和商业化的障碍。此外，某些检测方法（尤其是在检测潜伏性结核病方面）的诊断准确性存在差异，以及区分结核病与其他呼吸道感染疾病的持续挑战，也给临床决策带来了障碍，从而影响了市场的成长。

市场机会

结核病诊断市场蕴藏着巨大的成长机会，这得益于新型分子技术、数位医疗工具的整合以及日益加强的公私合作，旨在改善结核病的检测和治疗效果。对能够同时检测结核病和其他呼吸道感染疾病的多疾病检测平台的日益关注，正在提升诊断投资的商业性可行性。此外，国际卫生组织和各国政府不断增加的资金投入，正在支持开发和部署针对高负担地区、经济实惠、快速便捷且用户友好的结核病诊断方法。策略伙伴关係、研发投入以及创新诊断产品（例如基于次世代定序的检测方法和可携式核酸扩增检测 (NAAT) 设备）的推出，对于抓住这些机会并在不断发展的结核病诊断领域保持市场领先地位至关重要。

本报告研究了全球结核病诊断市场，并对市场动态进行了详细分析，包括成长动力、趋势、机会和挑战。

目录

第一章执行摘要

第二章 市场概述

  • 市场范围和定义
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
    • 任务
    • 主要趋势
  • 宏观经济因素
    • 全球产业展望
    • 全球GDP成长前景
  • COVID-19影响分析
  • 预测因子－相关性和影响力

第三章 增值考虑

  • 产品采用分析
  • 价值链分析
  • 监管情景
  • 重大交易及合併
  • PESTLE分析
  • 波特五力分析

4. 全球结核病诊断市场展望

  • 主要亮点
    • 市场规模及年成长
    • 绝对的商机
  • 市场规模分析及预测
    • 市场规模表现分析（2019-2024）
    • 市场规模分析与预测（2025-2032）
  • 全球结核病诊断市场展望：检测类型
    • 简介/主要发现
    • 历史市场规模分析：依测试类型（2019-2024）
    • 按测试类型分類的市场规模分析和预测（2025-2032）
      • 核酸检测
      • 涂片显微镜检查
      • 放射线检查
    • 市场吸引力分析：测试类型
  • 全球结核病诊断市场展望：最终用户
    • 简介/主要发现
    • 按最终用户分類的市场规模绩效分析（2019-2024 年）
    • 最终用户的市场规模分析与预测（2025-2032）
      • 医院和诊所
      • 诊断中心
      • 其他的
    • 市场吸引力分析：最终用户

5. 全球结核病诊断市场（按地区）展望

  • 主要亮点
  • 市场规模绩效分析：按地区（2019-2024）
  • 各地区市场规模分析及预测（2025-2032）
    • 北美洲
    • 欧洲
    • 东亚
    • 南亚和大洋洲
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：地区

6. 北美结核病诊断市场展望

7. 欧洲结核病诊断市场展望

8. 东亚结核病诊断市场展望

9. 南亚和大洋洲结核病诊断市场展望

10. 拉丁美洲结核病诊断市场展望

11.中东和非洲结核病诊断市场展望

第十二章竞争格局

  • 市场占有率分析（2025年）
  • 市场结构
    • 竞争强度图：按市场
    • 竞争仪錶板
  • 公司简介（详情－概述、财务状况、策略、最新发展）
    • Abbott
    • QIAGEN
    • Thermo Fisher Scientific Inc.
    • BD
    • F. Hoffmann-La Roche AG
    • Hologic, Inc.
    • Cepheid
    • DiaSorin SpA
    • Hain Lifescience GmbH
    • Oxford Immunotec
    • 其他的

第十三章 附录

简介目录
Product Code: PMRREP34779

Persistence Market Research has recently released a comprehensive report on the worldwide market for tuberculosis diagnostics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global tuberculosis diagnostics market from 2025 to 2032.

Key Insights:

  • Tuberculosis Diagnostics Market Size (2025E): USD 2.4 Billion
  • Projected Market Value (2032F): USD 3.5 Billion
  • Global Market Growth Rate (CAGR 2025 to 2032): 5.5%

Tuberculosis Diagnostics Market - Report Scope:

Tuberculosis diagnostics play a critical role in the detection and management of tuberculosis (TB), a major infectious disease with significant global health implications. These diagnostic tools range from traditional smear microscopy to advanced molecular assays that offer rapid and precise detection of Mycobacterium tuberculosis and drug resistance patterns. The tuberculosis diagnostics market serves various healthcare settings, including hospitals, diagnostic laboratories, clinics, and point-of-care facilities, offering a diverse portfolio of tests such as culture-based methods, nucleic acid amplification tests (NAATs), tuberculin skin tests, interferon-gamma release assays (IGRAs), and radiographic examinations. Market growth is driven by the persistent global burden of tuberculosis, rising initiatives for early detection and disease control, and technological advancements improving test accuracy and turnaround times.

Market Growth Drivers:

The global tuberculosis diagnostics market is propelled by several key factors, including the sustained high incidence of tuberculosis, especially in developing regions with inadequate healthcare infrastructure. Growing global initiatives, such as the WHO's End TB Strategy, emphasize early diagnosis and effective treatment, fueling the demand for innovative diagnostic solutions. Technological advancements, including the development of rapid molecular diagnostics and automated platforms, enhance detection rates and facilitate drug-resistance profiling, enabling better patient management and outbreak control. Moreover, the increasing adoption of point-of-care testing solutions expands access to timely TB diagnosis, particularly in resource-limited settings, further driving market expansion.

Market Restraints:

Despite promising growth prospects, the tuberculosis diagnostics market faces challenges related to high costs of advanced diagnostic tests, limited laboratory infrastructure in low-income regions, and social stigma associated with TB, which can hinder timely testing and diagnosis. Complex regulatory requirements and lengthy approval processes for new diagnostic products also pose barriers for market entry and commercialization. Additionally, the variability in diagnostic accuracy of certain tests, particularly in latent TB detection, and the ongoing challenge of differentiating TB from other respiratory infections create hurdles in clinical decision-making, impacting market growth.

Market Opportunities:

The tuberculosis diagnostics market presents significant growth opportunities driven by emerging molecular technologies, integration of digital health tools, and rising public-private collaborations to improve TB detection and treatment outcomes. The increasing focus on multi-disease testing platforms that can detect TB alongside other respiratory infections enhances the commercial viability of diagnostic investments. Furthermore, rising funding from global health organizations and governments supports the development and deployment of affordable, rapid, and user-friendly TB diagnostics tailored for high-burden regions. Strategic partnerships, investments in research and development, and the launch of innovative diagnostic products, such as next-generation sequencing-based assays and portable NAAT devices, are essential to capitalize on these opportunities and sustain market leadership in the evolving TB diagnostics landscape.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the tuberculosis diagnostics market globally?
  • Which diagnostic methods and applications are fueling TB testing adoption across different healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the tuberculosis diagnostics market?
  • Who are the key players contributing to the tuberculosis diagnostics market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global tuberculosis diagnostics market?

Competitive Intelligence and Business Strategy:

These companies invest in R&D to develop advanced diagnostic solutions, including rapid molecular assays, automated testing systems, and portable diagnostic devices, addressing the diverse needs of high-burden regions and resource-limited settings. Partnerships with governments, non-governmental organizations, and global health agencies facilitate market access and promote adoption of novel TB diagnostics. Moreover, emphasis on cost-effective solutions, decentralized testing, and digital integration fosters market growth and supports public health efforts to reduce TB incidence and mortality rates worldwide.

Key Companies Profiled:

  • Abbott
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • BD
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Cepheid
  • DiaSorin S.p.A.
  • Hain Lifescience GmbH
  • Oxford Immunotec
  • Others

Tuberculosis Diagnostics Market Research Segmentation:

The tuberculosis diagnostics market encompasses a diverse range of tests, technologies, applications, and end-user segments, addressing various patient populations and clinical needs.

By Test Type

  • Nucleic Acid Testing
  • SMEAR Microscopy
  • Radiography Tests

By End User

  • Hospitals & Clinics
  • Diagnostics Centres
  • Others

By Region

  • North America
  • Latin America
  • Europe
  • South Asia & Oceania
  • East Asia
  • The Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Tuberculosis Diagnostics Market Snapshot, 2025 and 2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Value Chain Analysis
  • 3.3. Regulatory Scenario
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Tuberculosis Diagnostics Market Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Tuberculosis Diagnostics Market Outlook: Test Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Test Type, 2019-2024
    • 4.3.3. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
      • 4.3.3.1. Nucleic Acid Testing
      • 4.3.3.2. SMEAR Microscopy
      • 4.3.3.3. Radiography Tests
    • 4.3.4. Market Attractiveness Analysis: Test Type
  • 4.4. Global Tuberculosis Diagnostics Market Outlook: End User
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2024
    • 4.4.3. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
      • 4.4.3.1. Hospitals & Clinics
      • 4.4.3.2. Diagnostics Centres
      • 4.4.3.3. Others
    • 4.4.4. Market Attractiveness Analysis: End User

5. Global Tuberculosis Diagnostics Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.3. Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Tuberculosis Diagnostics Market Outlook

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Test Type
    • 6.2.3. By End User
  • 6.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 6.4.1. Nucleic Acid Testing
    • 6.4.2. SMEAR Microscopy
    • 6.4.3. Radiography Tests
  • 6.5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 6.5.1. Hospitals & Clinics
    • 6.5.2. Diagnostics Centres
    • 6.5.3. Others
  • 6.6. Market Attractiveness Analysis

7. Europe Tuberculosis Diagnostics Market Outlook

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Test Type
    • 7.2.3. By End User
  • 7.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Rest of Europe
  • 7.4. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 7.4.1. Nucleic Acid Testing
    • 7.4.2. SMEAR Microscopy
    • 7.4.3. Radiography Tests
  • 7.5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 7.5.1. Hospitals & Clinics
    • 7.5.2. Diagnostics Centres
    • 7.5.3. Others
  • 7.6. Market Attractiveness Analysis

8. East Asia Tuberculosis Diagnostics Market Outlook

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Test Type
    • 8.2.3. By End User
  • 8.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 8.4.1. Nucleic Acid Testing
    • 8.4.2. SMEAR Microscopy
    • 8.4.3. Radiography Tests
  • 8.5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 8.5.1. Hospitals & Clinics
    • 8.5.2. Diagnostics Centres
    • 8.5.3. Others
  • 8.6. Market Attractiveness Analysis

9. South Asia & Oceania Tuberculosis Diagnostics Market Outlook

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Test Type
    • 9.2.3. By End User
  • 9.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 9.4.1. Nucleic Acid Testing
    • 9.4.2. SMEAR Microscopy
    • 9.4.3. Radiography Tests
  • 9.5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 9.5.1. Hospitals & Clinics
    • 9.5.2. Diagnostics Centres
    • 9.5.3. Others
  • 9.6. Market Attractiveness Analysis

10. Latin America Tuberculosis Diagnostics Market Outlook

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Test Type
    • 10.2.3. By End User
  • 10.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 10.4.1. Nucleic Acid Testing
    • 10.4.2. SMEAR Microscopy
    • 10.4.3. Radiography Tests
  • 10.5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 10.5.1. Hospitals & Clinics
    • 10.5.2. Diagnostics Centres
    • 10.5.3. Others
  • 10.6. Market Attractiveness Analysis

11. Middle East & Africa Tuberculosis Diagnostics Market Outlook

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Test Type
    • 11.2.3. By End User
  • 11.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 11.4.1. Nucleic Acid Testing
    • 11.4.2. SMEAR Microscopy
    • 11.4.3. Radiography Tests
  • 11.5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 11.5.1. Hospitals & Clinics
    • 11.5.2. Diagnostics Centres
    • 11.5.3. Others
  • 11.6. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Abbott
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. QIAGEN
    • 12.3.3. Thermo Fisher Scientific Inc.
    • 12.3.4. BD
    • 12.3.5. F. Hoffmann-La Roche AG
    • 12.3.6. Hologic, Inc.
    • 12.3.7. Cepheid
    • 12.3.8. DiaSorin S.p.A.
    • 12.3.9. Hain Lifescience GmbH
    • 12.3.10. Oxford Immunotec
    • 12.3.11. Others

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations